Cargando…

CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience

BACKGROUND: Calcitonin gene-related peptide (CGRP) (receptor) antibodies (erenumab, fremanezumab and galcanezumab) are increasingly used in prophylactic treatment of migraine. In the approval studies, severely affected patients with migraine and chronic daily headache without any headache free days...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scheffler, Armin, Schenk, Hannah, Wurthmann, Sebastian, Nsaka, Michael, Kleinschnitz, Christoph, Glas, Martin, Holle, Dagny
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Milan 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454157/ https://www.ncbi.nlm.nih.gov/pubmed/34544359 http://dx.doi.org/10.1186/s10194-021-01323-6

Ejemplares similares

Real‐world evidence following a mandatory treatment break after a 1‐year prophylactic treatment with calcitonin gene‐related peptide (pathway) monoclonal antibodies
por: Nsaka, Michael, et al.
Publicado: (2022)

Erenumab in highly therapy-refractory migraine patients: First German real-world evidence
por: Scheffler, Armin, et al.
Publicado: (2020)

Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study
por: Schenk, Hannah, et al.
Publicado: (2022)

Reduced vestibular perception thresholds in persistent postural-perceptual dizziness- a cross-sectional study
por: Wurthmann, Sebastian, et al.
Publicado: (2021)

Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor: Addition to the S1 guideline: Therapy of migraine attacks and prevention of migraine. Recommendations of the Germany Society of Neurology and the German Migraine and Headache Society
por: Diener, Hans-Christoph, et al.
Publicado: (2020)

CGRP in migraine
por: Tfelt-Hansen, Peer, et al.
Publicado: (2009)

CGRP and migraine
por: Cauchi, M., et al.
Publicado: (2016)

CGRP in Primary Headaches
por: Edvinsson, Lars
Publicado: (2001)

Real-world evidence on the economic implications of CGRP-mAbs as preventive treatment of migraine
por: Siersbæk, Nikolaj, et al.
Publicado: (2023)

Serotonin and CGRP in Migraine
por: Aggarwal, Milan, et al.
Publicado: (2012)

Effectiveness and Safety of CGRP-mAbs in Menstrual-Related Migraine: A Real-World Experience
por: Silvestro, Marcello, et al.
Publicado: (2021)

CGRP-induced migraine-like headache in persistent post-traumatic headache attributed to mild traumatic brain injury
por: Ashina, Håkan, et al.
Publicado: (2022)

Recent advances in the management of migraine
por: Obermann, Mark, et al.
Publicado: (2016)

Long-Term Effect of Switching From an Anti-CGRP Receptor to an Anti-CGRP Ligand Antibody in Treatment-Refractory Chronic Migraine: A Prospective Real-World Analysis
por: Lambru, Giorgio, et al.
Publicado: (2023)

Methodological considerations on real-world evidence studies of monoclonal antibodies against the CGRP-pathway for migraine: a systematic review
por: Vandenbussche, Nicolas, et al.
Publicado: (2023)

Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine
por: Berman, Gary, et al.
Publicado: (2020)

Change of CGRP Plasma Concentrations in Migraine after Discontinuation of CGRP-(Receptor) Monoclonal Antibodies
por: Raffaelli, Bianca, et al.
Publicado: (2023)

Gender aspects of CGRP in migraine
por: Labastida-Ramírez, Alejandro, et al.
Publicado: (2017)

CGRP and the Trigeminal System in Migraine
por: Iyengar, Smriti, et al.
Publicado: (2019)

Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine
por: Mechtler, Laszlo, et al.
Publicado: (2022)

Future targets for migraine treatment beyond CGRP
por: Al-Hassany, Linda, et al.
Publicado: (2023)

Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: A real-world cohort study
por: Overeem, Lucas Hendrik, et al.
Publicado: (2023)

CGRP and Migraine: What Have We Learned From Measuring CGRP in Migraine Patients So Far?
por: Kamm, Katharina
Publicado: (2022)

Refractory migraine profile in CGRP‐monoclonal antibodies scenario
por: Silvestro, Marcello, et al.
Publicado: (2021)

Monoclonal antibodies for chronic migraine and medication overuse headache: A real-world study
por: Krymchantowski, Abouch V., et al.
Publicado: (2023)

CGRP and migraine: neurogenic inflammation revisited
por: Geppetti, P., et al.
Publicado: (2005)

CGRP receptors and TRP channels in migraine
por: Geppetti, Pierangelo, et al.
Publicado: (2015)

CGRP as a Migraine Inducing Substance
por: Olesen, J., et al.
Publicado: (2001)

Dural Immune Cells, CGRP, and Migraine
por: Balcziak, Louis K., et al.
Publicado: (2022)

Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy
por: Scuteri, Damiana, et al.
Publicado: (2021)

Resumption of migraine preventive treatment with CGRP(-receptor) antibodies after a 3-month drug holiday: a real-world experience
por: Raffaelli, Bianca, et al.
Publicado: (2022)

Persistent Postural-Perceptual Dizziness: A Matter of Higher, Central Dysfunction?
por: Holle, Dagny, et al.
Publicado: (2015)

Is prednisone still a reasonable option in the treatment of withdrawal headache in patients with chronic migraine and medication overuse headache in the age of CGRP antibodies? A narrative review
por: Kaltseis, Katharina, et al.
Publicado: (2022)

Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(−receptor) antibodies
por: Terhart, Maria, et al.
Publicado: (2021)

Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
por: Tso, Amy R., et al.
Publicado: (2017)

Hypervigilance, Allostatic Load, and Migraine Prevention: Antibodies to CGRP or Receptor
por: Blumenfeld, Andrew, et al.
Publicado: (2021)

CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
por: Schiano di Cola, Francesca, et al.
Publicado: (2022)

Migraine therapeutics differentially modulate the CGRP pathway
por: Bhakta, Minoti, et al.
Publicado: (2021)

Pooled Analysis of Real-World Evidence Supports Anti-CGRP mAbs and OnabotulinumtoxinA Combined Trial in Chronic Migraine
por: Scuteri, Damiana, et al.
Publicado: (2022)

Impact of a 12-week open-label placebo treatment on headache days in episodic and chronic migraine: a study protocol for a parallel-group, multicentre, randomised controlled trial
por: Schmidt, Katharina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_arevorvm1blsv2jeob529d9etg